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Abstract
Background: Anxiety is highly prevalent in people diagnosed with bipolar disorder (BD), and can persist between
acute episodes of mania and depression. Recent studies indicate that people with BD are prone to experiencing
frequent, intrusive and emotional mental images which further fuel their levels of anxiety and mood instability.
These intrusive emotional mental images represent a specific target for treatment for this disorder with the
potential to reduce anxiety and improve mood stability. A new brief structured psychological intervention for BD
called Imagery Based Emotion Regulation (IBER) has been developed, which translates experimental work in the
area of imagery and emotion into a skills training programme to improve the regulation of intrusive and distressing
emotional mental images in BD. A feasibility trial is required in order to assess whether a full randomised controlled
trial is indicated in order to evaluate this approach.
Methods: The design is a two-arm feasibility randomised controlled trial (RCT), with 1:1 randomisation stratified by
trial site and minimised on medication status and anxiety severity. Participants are 60 individuals diagnosed with
bipolar disorder and experiencing at least a mild level of anxiety. Sites are defined by the geographical boundaries
of two National Health Service (NHS) Trusts, with recruitment from NHS teams, GP surgeries and self-referral. The
intervention is up to 12 sessions of Imagery Based Emotion Regulation within 16 weeks. The comparator is NHS
standard care. The primary aim is to assess the feasibility of conducting a powered multi-site RCT to evaluate
effectiveness. Measures of anxiety, depression, mania, mood stability and health care use will be conducted at
baseline, end of treatment and at 16-week follow-up.
Discussion: This is the first feasibility trial of an imagery-based intervention for the treatment of anxiety in bipolar
disorder. If the trial proves feasible, a large multi-site trial will be required.
Trial registration: ISRCTN16321795. Registered on October 16, 2018. https://doi.org/10.1186/ISRCTN16321795
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Background
Bipolar disorder (BD) has the highest rate of suicide of
all psychiatric disorders, with up to 50% attempting sui-
cide at least once [1]. It is highly recurrent and projected
to cost the UK economy £8.2 billion per annum by 2026
[2]. Most treatments (psychosocial and pharmacological)
for BD target the important outcomes of depression and
relapse rates. However, current National Institute for
Health and Clinical Excellent (NICE) guidelines [3] state
that the evidence base of psychosocial interventions for
BD is mainly of low quality. Trials have produced mixed
results and due to the lack of a strong evidence base,
NICE currently suggest a range of options derived from
the outcomes of low to moderate quality trials. These in-
clude group interventions, psychoeducation, family-
focused therapy, cognitive behavioural therapy (CBT),
interpersonal and social rhythm therapy and integrated
cognitive and interpersonal therapy. There is, therefore,
a clear need to develop innovative interventions which
directly target the mechanisms underlying mood
instability.
Anxiety is highly prevalent in BD, and can persist be-
tween acute episodes of mania and depression [4–6].
Anxiety within BD is associated with increased levels of
suicide, relapse, higher levels of mood fluctuation and a
hampered treatment response to mood stabilisers such
as lithium [7–9]. Recent studies indicate that people with
BD are particularly vulnerable to experiencing frequent,
intrusive and emotional mental images [6, 10] which fuel
anxiety and mood instability. These images are some-
what similar to the intrusive mental ‘flashbacks’ associ-
ated with posttraumatic stress disorder (PTSD).
However, intrusive mental images in BD are typically as-
sociated with imagined, emotionally intense, future
events or ‘flashforwards’ e.g. an image of attempting sui-
cide (fueling anxiety), or of winning a Nobel prize (fuel-
ing elation). Neuroimaging studies indicate that
imagining an event provokes a similar response within
the visual cortex to experiencing the event ‘for real’. This
is likely to explain findings that image-based thought
(e.g. imagining jumping off a building) induces a stron-
ger emotional reaction than verbal–based thought (e.g.
thinking purely in words about the idea of jumping off a
building) [11]. Patients with BD report experiencing
these mental images as ‘lifelike’, hard to ignore and diffi-
cult to control when compared to people diagnosed with
other mental health problems [5, 6, 10, 12]. The intru-
sive emotional mental images which are highly prevalent
in BD therefore represent a specific target for treatment
for this disorder with the potential to reduce anxiety and
improve mood stability [6, 13]. Further, the recent treat-
ment guidelines for BD from the British Association of
Psychopharmacology [14] warn of the potential adverse
effects of selective serotonin reuptake inhibitors in BD
and state that ‘Psychological treatments potentially offer
adjunctive approaches for addressing anxiety in bipolar
disorder where anxiety-specific medication is counter-
indicated and/or in line with a patient’s preference’
(pg.537).
The most widely adopted form of psychological ther-
apy within the NHS is CBT. Whilst effective for a num-
ber of disorders [15], at best CBT has produced low to
moderate effects in trials targeting depression and re-
lapse prevention in BD [16, 17]. CBT requires patients
to engage in a logical verbal discussion about their emo-
tions. Therefore, it may be that the processes adopted
within CBT are not best suited to tackling emotional im-
ages within BD. Given the proposal that emotional im-
ages underlie the anxiety present in BD, it is of note that
that the only study of CBT for anxiety in this group did
not produce positive results [18]. There is, therefore, a
need to develop a psychological intervention for BD
which is distinct from traditional CBT and which im-
proves outcomes for those diagnosed with this disabling
condition.
Research in the field is also limited due to an over-
reliance on the assessment of mood at a single time-
point. This method fails to capture the inherent
mood instability in BD. The current trial adopts an
innovative, yet simple, measure of mood stability to
capture this outcome. The use of single mood ratings
collected every day over a 28-day period has been
shown to be feasible (over 95% of data captured in
our case series [19]).
We have developed a new brief structured psycho-
logical intervention for BD called Imagery Based
Emotion Regulation (IBER). The treatment translates
our experimental work in the area of imagery and
emotion into a skills training programme to improve
the regulation of intrusive and distressing emotional
mental images in BD. IBER also contains a positive
imagery module suitable for the small minority of BD
patients who may not report anxiety-related mental
images [6, 10]. It is proposed that the intervention
can be delivered by mental health professionals who
have received training in psychological therapies.
An early version of our intervention was adapted after
input from service-users, and an improved version was
then evaluated within a recently published case series
[19]. Results from 14 participants indicated a Cohen’s d
pre-post effect size for anxiety of 1.89 along with re-
duced levels of depression, improved mood stability and
a high level of engagement with treatment. The specific
targeting of one mechanism provides a focused interven-
tion, which requires fewer sessions than other current
psychological treatments. The potential to reduce anx-
iety, mood instability and relapse rates within this group
is of clear health benefit to patients and has potential
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economic benefit to the NHS. A feasibility study is re-
quired to determine whether a full trial is indicated.
Aim and objectives
The overall aim is to assess the feasibility and acceptabil-
ity of a future definitive trial to evaluate the clinical and
cost-effectiveness of IBER for reducing anxiety within
adults with BD. The objectives are as follows:
1. To inform the recruitment and timeline of a full
trial, by establishing the number of participants
identified, approached, consented and randomised
within a fixed period along with the participant
retention rates for follow-up assessment and com-
pletion of intervention
2. To inform the sample size estimation of a future
trial
3. To refine trial procedures by establishing the
acceptability of the trial process to participants
including randomisation and participant-perceived
relevance and burden of the outcome measures
4. To further assess the acceptability of the treatment
and, based on input from trial participants and
clinicians, to further refine and develop the
treatment manual and the procedures for training,
supervising and assessing the competence of trial
therapists
Method
Design
A feasibility study with a two-arm randomised parallel
controlled trial design: 60 participants will be allocated
to standard care (SC) or Imagery Based Emotion Regula-
tion programme plus standard care (IBER + SC).
Patients will be randomised on a 1:1 ratio with stratifi-
cation by trial site and minimised on medication status
(i.e. prescribed mood stabilisers) and anxiety severity (se-
vere anxiety being a score above 14 on a measure on the
Generalised Anxiety Disorder Assessment (GAD-7 [20]))
to the control or intervention arm. Web-based random-
isation will be carried out independently, by the Thames
Valley Clinical Trials Unit (TVCTU), using randomised
permuted blocks.
Assessments will be conducted at 0 (baseline, prior to
randomisation), 4 (end of treatment) and 8months (fol-
low-up) post-randomisation through self-report ques-
tionnaires, which will be completed via an online
questionnaire system or through paper questionnaires
which are posted back to the research assistant or col-
lected in person. Research assistants will be blind to
group allocation.
The CONSORT (Consolidated Standards of Reporting
Trials; http://www.consort-statement.org/) extension to
randomised pilot and feasibility trials statement will be
followed in reporting the trial [21]. Information on the
protocol is detailed in the SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials) fig-
ure (see Table 1 and the Checklist in the Additional file
1).
Setting
The setting will be secondary NHS community and in-
patient services, primary care and self-referral within the
geographical boundaries of two NHS Trusts: Berkshire
Healthcare NHS Foundation Trust and Devon Partner-
ship Foundation Trust.
Participants
Participants will be 60 individuals with bipolar disorder.
Inclusion criteria
1. DSM-5 diagnosis of bipolar disorder (I, II or
otherwise specified) assessed using the Structured
Clinical Interview for DSM-5 (SCID) [22].
2. Aged 18 or above
3. Score 5 or above on the GAD-7 [20]
4. Sufficient understanding of English in order to be
able to engage in the study
5. To have completed all baseline assessments, and at
least 23 out of the 28 daily mood monitoring
measurements conducted at baseline (see below)
Exclusion criteria
1. Currently within an episode of mania or depression
2. Unable to provide informed consent
3. Acute suicide risk
4. DSM-5 diagnosis of substance use or alcohol use
disorder, moderate or severe, assessed using the
SCID [22]
5. A change in medication within 3 months prior to
randomisation
6. Currently engaged in a psychological intervention
Trial flowchart
Figure 1 illustrates the trial flowchart.
Interventions
Intervention: Imagery Based Emotion Regulation (IBER)
IBER is a structured intervention delivered via 12 1-h in-
dividual sessions to be completed within 4 months. IBER
involves training individuals to be able to modify and
regulate their emotional reactions to intrusive mental
images, and is comprised three stages:
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Assessment
The assessment of current coping strategies and, where
necessary, the development of a crisis management plan.
The therapist then assesses the occurrence of intrusive
mental images, including how many different images
occur, how often and with what emotional impact. A
personalised treatment plan is then developed in which
the most significantly distressing images are identified
for treatment.
Treatment
Four distinct theoretically informed modules have
been developed as outlined below. Each distressing
image is treated through training the patient in one
or more of the following four techniques and
strategies.
(i) Imagery rescripting (IR). Adapted from an
intervention used with PTSD Participants are
trained to gain control over the content of a
repetitive distressing image, and therefore to be able
to moderate their emotional reaction.
(ii) Visual imagery techniques (VIT). As with IR
above, VIT involves techniques that enable
control over the content of distressing images.
These techniques are useful with a range of
images, but less potent than IR for dealing with
one specific repetitive image. The desired
outcome is that participants learn that distressing
images are not ‘real’ and are not necessarily
accurate representations of their past or future.
(iii)Positive imagery. Provides skills in positive,
mood-enhancing or soothing imagery which is
often lacking in patients with BD. The aim is to
utilise the imagery skills often present in BD to
the individual’s advantage, and therefore this ap-
proach is suitable for the minority of participants
who do not report experiencing intrusive anxiety-
related images.
(iv)Competing tasks. Based on extensive
experimental work, participants are taught to
engage in certain exercises which occupy an
individual’s visuo-spatial resources. Engaging in
these exercises, for example the computer game
‘Tetris’, is associated with a reduction in the fre-
quency of intrusive images. This approach is
most likely to be used with the most severely
distressed participants before moving onto one or
more of the skills described above.
Consolidation
The skills that have been learnt are consolidated into an
action plan that the participant can draw on once the
intervention is complete. The ‘visual thinking style’ asso-
ciated with BD is harnessed through the development of
a personal video which captures the action plan in im-
ages as well as words.
Table 1 The Standard Protocol Items (SPIRIT) for a feasibility study of Imagery Based Emotion Regulation to treat anxiety in bipolar
disorder (the IBER study): schedule of enrolment, interventions and assessments
Enrolment Baseline Allocation Post-intervention 16-week follow-up
Timepoint** t1 t2 t3
Enrolment
Eligibility screen X
Informed consent X
[List other procedures]
Allocation X
Interventions
[Imager Based Emotion Regulation] X
[Standard care] X
Assessments
[28-day mood monitoring] X X X
[Generalised Anxiety Disorder Assessment] X X X
[Quick Inventory of Depressive Symptomatology–Self Report] X X X
[Self-Rating Scale for Mania] X X X
[Health Economics Questionnaire] X X X
[ICECAP-A] X X X
[EuroQol EQ-5D-5 L] X X X
[OxCAP-MH] X X X
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Comparator
Both intervention and the comparator groups will re-
ceive NHS standard care (SC), likely to include the
development of a risk management plan, offering life-
style advice, including good sleeping habits and cop-
ing strategies, structured psychiatric assessment of
mood, physical health and social factors and pharma-
cological treatment for acute episodes and long-term
management.
Treatment and intervention acceptability
Trial acceptability will be assessed via written open-
ended questions about the length, time needed and
acceptability of outcome measures, and views about
other trial procedures. Data will be collected from all
participants in both trial arms, separately from and
following the 8-month assessment. Data will be ana-
lysed descriptively, with some basic content/thematic
analysis of open-ended responses.
Intervention acceptability will be assessed via a service
user informed semi-structured interview, conducted with
50% of the treatment arm (n = 15). Views of therapists
delivering the intervention will be obtained via semi-
structured interviews. All interviews will be audio-
recorded, transcribed and analysed using thematic ana-
lysis in order to inform further possible refinements of
the intervention and its delivery.
Measures
The following measures are those proposed for use
within a future definitive trial and are employed to fulfill
the aims of the current feasibility study.
Fig. 1 Trial flowchart for the IBER trial feasibility RCT protocol
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Measurements in bipolar disorder
Previous studies have relied on the assessment of mood
taken at one timepoint. This approach fails to capture
the mood instability inherent in BD and is prone to
error.
Outcomes include anxiety (primary outcome), depres-
sion and mania (secondary outcomes). Each of these is
measured using self-report questionnaires covering the
previous 7 days. Each symptom is measured by adminis-
tering questionnaires on four separate occasions, 1 week
apart, covering a 28-day period. The mean value will be
used. Baseline data will cover the 28 days prior to ran-
domisation, and follow-up data will cover the 28 days
after each follow-up assessment due date (at 4 months
and 8months post randomisation).
Mood stability is measured through participants rating
(0–6) how anxious, elated, sad and angry they feel on a
daily basis over the same 28-day period at baseline, 4-
month follow-up and 8-month follow-up. Data analysis
produces a measure of mood stability for each of the
four emotions, and a combined mood stability score.
Main outcome
Anxiety: GAD-7 [20], a validated 7-item self-report
measure of anxiety is widely used within NHS services.
Secondary outcomes
Depression: Quick Inventory of Depressive Symptom-
atology–Self Report (QIDS-SR) [23], a validated 16-item
measure of depression
Mania: Altman Self-Rating Scale for Mania (ASRM)
[24], a validated 5-item self-report questionnaire for de-
tecting mania within BD patients
Mood stability: measured over a 28-day period
through the response to four mood questions (anxious,
elated, sad and angry; scale 0–6) via online or paper as-
sessments. Mood variability is quantified using the
standard deviation, Teager-Kaiser energy operator and
the root mean squared successive differences for each of
the four daily mood measure items, and for combined
mood.
Resource use and costs: the Health Economics Ques-
tionnaire (HEQ), [25] a comprehensive patient self-
completed health economics questionnaire measuring
health and social care resource use, medication, informal
care, presence and absenteeism from work as well as
socio-demographic background information
Quality of life: the EuroQol EQ-5D-5 L [26], a widely
used generic health-related quality of life measure, and
two broader well-being questionnaires, the Icepop Cap-
ability measure for Adults (ICECAP-A) [27] and the Ox-
ford Capabilities questionnaire-Mental Health (OxCAP-
MH) [28], two outcome instruments based on Sen’s cap-
ability approach but with different conceptual profiles,
one more generic, the other one developed specifically
for mental health outcome measurement
Procedure
Participants will be identified through NHS teams, gen-
eral practitioner surgeries and self-referral. For NHS
teams, research assistants will discuss the trial with NHS
staff who will in turn provide information on the trial to
those patients who may be eligible. Patients who consent
to being approached by the research team to discuss the
trial further, will be provided with more information. GP
surgeries within the geographical boundaries of the two
participating NHS Trusts will be asked to conduct a
search and post information on the trial to those poten-
tially eligible on their patient lists. We will also provide
self-referral posters within the Trusts as well as promote
the trial upon relevant websites, such as Bipolar UK.
The point of contact for all referrals and self-referrals
will be the research assistants, who will be trained in
Good Clinical Practice, and go through the participant
information sheet and obtain informed consent from
those who are interested. This will be followed by com-
pleting the assessments which will determine eligibility,
including the GAD-7 [20] in which a minimum score of
5 (mild anxiety) is required, followed by the SCID [22]
to assess for a current diagnosis of bipolar disorder,
along with recording information of any other anxiety or
depressive disorders, and the demographic information.
Once eligibility is established, the participant completes
the baseline assessment measures using the online data
system adopted within the current trial. This system is
used to capture all the data from the main and second-
ary outcome measures of the trial. In the 28 days after
consent, participants are to complete daily mood ratings
every day for 28 days. If an individual fails to complete at
least 23 of these 28 daily ratings then they are excluded
from the trial prior to randomisation. They are also to
complete measures of anxiety, depression and mania
every week within this 28-day period. On the final day of
the 28-day assessment period, randomisation to treat-
ment condition takes place. The participant is then ran-
domised to receive 16 weeks of either IBER or the
comparator. A member of the study team will inform
the participant of the outcome by telephone. At the end
of this period, another 28-day mood monitoring period
occurs including the same daily and weekly measures as
during the pre-randomisation baseline period. The start
of this 28-day period is also the start of a 16-week period
of post-intervention follow-up. At week 12 within the
follow-up period, another (and final) 28-day period of
daily and weekly mood monitoring begins, so as the final
day of mood monitoring coincides with the end of the
16-week follow-up period. Health economic data cap-
tured once every 28 days from the start of the trial, and
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throughout until the end of the follow-up. Participants
who do not wish to use the online data system will be
provided with paper copies of the assessments to use
throughout. Research assistants will remain blind to
treatment allocation throughout the trial, through using
separate records, room bookings and offices to the trial
therapists.
After trial completion all participants, including those
who dropped out of the main study, from both condi-
tions will be posted a short questionnaire to assess their
experiences of both the trial procedures (e.g. the mood
monitoring assessments) and the IBER intervention (for
those who received it). Also, a random 50% of those allo-
cated to received IBER intervention will be invited to
participate in a longer in-depth interview to extract
qualitative data from their experience.
Data analysis and presentation
We will not report significance tests as the feasibility
RCT was not designed or powered to test hypotheses or
to detect change. Given the feasibility objectives of this
study, the focus of data analysis will be descriptive.
1. Objective 1 (informing recruitment and testing
timeline) will be considered by summarising
participant flow across both sites, reporting mean
recruitment and attrition rates (both intervention
and study dropouts) with 95% confidence intervals.
The diagram will reflect the number of patients
approached, number consenting, number
randomised, number completing the intervention
(defined as attending at least 50% of sessions) and
number who completed the research outcome
measures alongside means and standard deviations
regarding the number, length and frequency of
sessions. All protocol deviations, along with reasons
and number of missing items on questionnaires will
be reported.
2. To address objective 2 (informing future sample
size estimation), mean and standard deviations of
the main outcome (anxiety) for both study arms
will be reported at baseline, four and 8 months.
3. To address objective 3 (acceptability of trial process
and measures), descriptive statistics will be
produced for quantitative acceptability data, whilst
qualitative data will be subject to thematic analysis.
4. To address objective 4 (acceptability of treatment,
refine treatment manual and procedures for
training, supervising and assessing therapist
competence), themes pertaining to treatment
acceptability from the exit interviews will be
described, and inter-rater reliability for the pro-
posed competency and fidelity measures will be
reported.
Feasibility for a full trial will be based on the following
criteria:
1. No serious negative consequences are associated
with trial participation.
2. Any concerns over the feasibility and acceptability
of a full trial can be rectified.
3. Overall recruitment at 80% or above within the 12-
month recruitment period
4. Eight-month follow-up data is obtained from at
least 80% of participants.
5. At least 80% of participants allocated to the
intervention group do not drop out (i.e. attend at
least 50% of the possible sessions).
Data management and security
Data confidentiality and secure storage will be ensured,
in line with the General Data Protection Regulation
2016/679. All personal data will be kept separately from
study data, so that study data will be anonymous. Partic-
ipants will be identified through a trial ID number. Per-
sonal data will be kept stored in line with the NHS Code
of Confidentiality. Therapy notes will be stored in line
with NHS Trust policy. The research data will be held
within a secure database, which will be password pro-
tected this ensuring access is only available to members
of the research team. All audio-recordings will be named
as the unique participant identifier and stored as com-
puter files on secure NHS servers in an anonymised and
encrypted form.
Data quality
Data quality will be ensured through close checking and
routine auditing. Given that it is anticipated that the vast
majority of participants will provide data via an online
system, the data obtained will be directly transferred to a
database for analysis. Data collected on paper will be
double checked after entry into the database.
Study governance
Project management will be organised at a number of
levels, with a part-time trial manager working alongside
the chief investigator (CI), who will have overall respon-
sibility for trial data.
Team management
The CI will chair full team meetings (fortnightly for the
first 6 months moving to monthly) to discuss all trial
management issues. On alternate meetings, two external
service users will be invited so as to contribute from an
advisory perspective.
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Local management
Each recruitment site will hold meetings (fortnightly
for the first 6 months moving to monthly) chaired by
the site lead (CS/KW) and involving the research as-
sistant (RA), service-user RA and local service/ R&D
representatives to discuss recruitment and other trial
activity.
Trial Steering Committee (TSC) will meet every 6
months and consist of three independent members, one
of whom will be the chair, the CI, and all PIs and an in-
vited observer representative.
Data Monitoring and Ethics Committee (DMEC) with
an independent chair will review adverse events and
monitor data.
The sponsor and REC will be provided with direct ac-
cess to source data and other documents if required for
trial review. The trial may be prematurely discontinued
by the sponsor, chief investigator on the basis of new
safety information or for other reasons by the DMEC.
Dissemination
We will publish outcomes in peer-reviewed journals
(open-access) and make our data available to the re-
search community via Open Science framework. We
will publish relevant data and outcomes in journals
aimed at psychological therapists, service user re-
searchers and health economists. We will file a full
report in the National Institute of Health Research
journals library. Team members will present at con-
ferences to access the wide range of audiences associ-
ated with the treatment of bipolar disorder, including
psychiatrists, psychological therapists, health care
commissioners, charities and self-help forums. We
will also disseminate via social media.
Discussion
There is a need for innovation in the development of
psychological interventions for bipolar disorder. Inter-
ventions which target specific mechanisms underlying
the mood stability inherent within bipolar disorder form
the basis of potentially effective new treatments. The
current feasibility trial is the first to explore the potential
of an imagery-based intervention for the treatment of
anxiety within this disabling condition. The results will
inform the development of a fully powered RCT as well
as facilitate the development of training materials and a
final manual of the intervention.
Trial status
Recruitment of participants commenced in October
2018 and will be open until January 2020. Current
protocol is v5.0 1.12.2018.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00628-8.
Additional file 1:. SPIRIT 2013 Checklist: Recommended items to
address in a clinical trial protocol and related documents*
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